Protect Pharmaceutical Innovation

摘要

In Her Policy Forum "Fixing The Legal framework for pharmaceutical research" (26 February, p. 1083, published online 11 February), GlaxoSmithKline attorney S. M. Knowles contends that the Hatch-Waxman Act should be altered to increase data exclusivity from 5 to 14 years. If implemented, this disturbing change would likely narrow the drug development pipeline and certainly increase drug prices.